Beximco Pharmaceuticals Limited announced the signing of a definitive agreement with Sandoz Inc. to acquire a portfolio of 8 Abbreviated New Drug Applications (ANDAs) in the US for an undisclosed amount in cash. Beximco Pharma's current US portfolio comprises 6 US Food and Drug Administration (FDA) approved products. Four of these products are currently being exported to the US and two products are awaiting regulatory approval. Following this transaction, Beximco Pharma's US portfolio will consist of 14 approved ANDAs.